Literature DB >> 15664071

Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium.

Kate S Cuschieri1, Gerry Beattie, Sameena Hassan, Kevin Robertson, Heather Cubie.   

Abstract

Little is known about the stability of human papillomavirus (HPV) RNA within cervical samples collected in liquid based cytology (LBC) preservation media. We addressed this by analysing patient LBC specimens for the presence of HPV RNA over a prospective time course. LBC samples in PreservCyt were obtained from seven women referred to colposcopy due to a cytological diagnosis of moderate or severe dyskaryosis. Aliquots were removed and subject to RNA extraction at, 6h (base-line), 4, 7 and 14 days, post-collection. HPV mRNA was detected using the PreTect HPV Proofer, which detects HPV 16, 18, 31, 33 and 45 E6/E7 transcripts and human small ribonucleoprotein U1A mRNA as a sample control. HPV DNA genotyping was also performed at base-line to assess the range of types in our group. In addition to assessment of viral RNA, overall integrity of the cellular RNA extract was analysed by the RNA 6000 pico assay. Control human RNA was amplified successfully in all seven samples at each time point. Five of the seven women were HPV positive for E6/E7 viral transcripts at base-line and positivity was maintained in all five up to 14 days. Although the pattern of cellular RNA profiles generated from the samples was variable, results indicated that this extract could be amenable to gene expression profiling and that degradation did not increase as a result of storage time. It is concluded that HPV RNA in routinely collected LBC specimens in PreservCyt can be detected for at least 14 days from sample collection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15664071     DOI: 10.1016/j.jviromet.2004.11.005

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  13 in total

1.  Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Authors:  A T Hesselink; N W J Bulkmans; J Berkhof; A T Lorincz; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

2.  mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer.

Authors:  Marta Del Pino; Cecilia Svanholm-Barrie; Aureli Torné; Lorena Marimon; Jina Gaber; Amaia Sagasta; David H Persing; Jaume Ordi
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

3.  High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Authors:  D C Rijkaart; D A M Heideman; V M H Coupe; A A T P Brink; R H M Verheijen; H Skomedal; F Karlsen; E Morland; P J F Snijders; C J L M Meijer
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

Review 4.  Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

Authors:  Kate Cuschieri; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

5.  Absolute quantitative real-time polymerase chain reaction for the measurement of human papillomavirus E7 mRNA in cervical cytobrush specimens.

Authors:  Michael E Scheurer; Laura M Dillon; Zhuo Chen; Michele Follen; Karen Adler-Storthz
Journal:  Infect Agent Cancer       Date:  2007-04-02       Impact factor: 2.965

6.  Analytic and Diagnostic Performances of Human Papillomavirus E6/E7 mRNA Test on up-to 11-Year-Old Liquid-Based Cervical Samples. A Biobank-Based Longitudinal Study.

Authors:  Roberta Zappacosta; Francesca Sablone; Lucia Pansa; Davide Buca; Danilo Buca; Sandra Rosini
Journal:  Int J Mol Sci       Date:  2017-07-11       Impact factor: 5.923

7.  Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples.

Authors:  Andrew Stevenson; Kim Kavanagh; Jiafeng Pan; Lynne Stevenson; Heather Griffin; John Doorbar; Evelyn Scott; Miriam Deeny; Kate Cuschieri; Sheila V Graham
Journal:  J Clin Virol       Date:  2018-08-31       Impact factor: 3.168

8.  Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.

Authors:  Sonya Naryshkin; R Marshall Austin
Journal:  Drug Healthc Patient Saf       Date:  2012-11-02

9.  Retrieval of HPV oncogenes E6 and E7 mRNA from cervical specimens using a manual open technology protocol.

Authors:  Leonardo Martins Campbell; Denise Rocha Pitta; Angela Maria De Assis; Sophie Francoise Mauricette Derchain; Elisabete Aparecida Campos; Luis Otavio Zanatta Sarian
Journal:  Springerplus       Date:  2013-09-18

10.  Assessing the detection of human papillomavirus late mRNA in liquid base cytology samples for risk stratification of cervical disease.

Authors:  George Chambers; David Millan; Kate Cuschieri; Heather A Cubie; Sheila V Graham
Journal:  J Med Virol       Date:  2013-10-19       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.